Genistein combined with FOLFOX or FOLFOX–Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study

Background Epidemiologic and preclinical data suggest isoflavones have anticancer activity in colorectal malignancy prevention and treatment. This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer. Methods Pati...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer chemotherapy and pharmacology Ročník 84; číslo 3; s. 591 - 598
Hlavní autoři:	Pintova, Sofya, Dharmupari, Sirish, Moshier, Erin, Zubizarreta, Nicole, Ang, Celina, Holcombe, Randall F.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2019 Springer Nature B.V
Témata:	Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Bevacizumab Bevacizumab - administration & dosage Bone Neoplasms - drug therapy Bone Neoplasms - secondary Cancer Cancer Research Chemotherapy Clinical trials Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Epidemiology Female Fluorouracil - administration & dosage Follow-Up Studies Genistein Genistein - administration & dosage Headache Humans Immunotherapy Isoflavones Leucovorin - administration & dosage Liver Neoplasms - drug therapy Liver Neoplasms - secondary Lung Neoplasms - drug therapy Lung Neoplasms - secondary Male Malignancy Medicine Medicine & Public Health Metastases Metastasis Middle Aged Monoclonal antibodies Nausea NCT NCT01985763 Oncology Oral administration Original Article Oxaliplatin - administration & dosage Patients Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - secondary Pharmacology/Toxicology Pilot Projects Prognosis Response rates Survival Rate Targeted cancer therapy Isoflavone Metastatic FOLFOX Genistein Colorectal cancer Bevacizumab
ISSN:	0344-5704, 1432-0843, 1432-0843
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!